1] Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA [2] Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Nat Mater. 2013 Nov;12(11):958-62. doi: 10.1038/nmat3792.
Cancer nanomedicines approved so far minimize toxicity, but their efficacy is often limited by physiological barriers posed by the tumour microenvironment. Here, we discuss how these barriers can be overcome through innovative nanomedicine design and through creative manipulation of the tumour microenvironment.
迄今为止，已获批的癌症纳米药物最大限度地降低了毒性，但它们的疗效往往受到肿瘤微环境带来的生理障碍的限制。在此，我们将讨论如何通过创新的纳米药物设计以及创造性地操控肿瘤微环境来克服这些障碍。
